What is the primary purpose of this 8-K filing?

This filing announces the successful completion of a consent solicitation by Pfizer to amend the terms of outstanding Wyeth notes after Pfizer's acquisition of Wyeth. It details the changes made to the governing indenture and Pfizer's assumption of responsibility for these notes.

What is the significance of Pfizer issuing a guarantee for Wyeth's notes?

Pfizer's unconditional and irrevocable guarantee means that Pfizer is now directly responsible for the timely payment of all amounts owed on Wyeth's notes. This provides enhanced security for the noteholders, as they now have the credit backing of Pfizer, a larger and likely more creditworthy entity.

Which specific provisions of the Wyeth indenture were amended?

The amendments affect provisions related to Wyeth's ability to merge or sell substantially all of its assets, limitations on incurring liens, limitations on sale and leaseback transactions, publication notice requirements in Luxembourg, cure periods for payment defaults, the annual compliance certificate delivery date, and Wyeth's obligation to file SEC reports with the Trustee.

Does this filing indicate any change in the interest rates or maturity dates of Wyeth's notes?

No, this filing does not indicate any changes to the interest rates or maturity dates of the specific Wyeth notes mentioned. The amendments primarily concern covenants and Pfizer's guarantee of existing obligations, not the core financial terms of the debt itself.

PFE 8-K SEC Disclosure

Summary

Pfizer Inc. (PFE) filed an 8-K on November 3, 2009, detailing the successful completion of a consent solicitation related to Wyeth's outstanding notes. Following the acquisition of Wyeth, Pfizer initiated the solicitation to amend certain provisions of the indenture governing these notes. The company received the required consents from a majority of the noteholders, allowing for the execution of an Eighth Supplemental Indenture on October 30, 2009. This supplemental indenture is significant as it introduces an unconditional and irrevocable guarantee from Pfizer for all amounts owed to holders of Wyeth's notes. Additionally, several covenants within the original indenture have been amended, impacting areas such as Wyeth's ability to engage in mergers or asset sales, incur liens, enter into sale and leaseback transactions, and its reporting obligations. These changes are crucial for integrating Wyeth's debt obligations under Pfizer's corporate structure.

Key Highlights

1Pfizer successfully completed a consent solicitation for Wyeth's notes, obtaining the necessary consents from a majority of noteholders.
2An Eighth Supplemental Indenture was executed on October 30, 2009, formalizing the consent solicitation outcomes.
3Pfizer issued an unconditional and irrevocable guarantee for all obligations related to Wyeth's outstanding notes.
4Several key provisions of the Wyeth indenture were amended, affecting consolidation/merger clauses, liens, sale and leaseback transactions, and reporting requirements.
5The filing confirms the integration of Wyeth's debt under Pfizer's guarantee following the acquisition.
6Exhibit 99.1 is a press release announcing the completion of the Wyeth acquisition, providing broader context for this filing.

PFIZER INC 8-K Report, Corporate Update (Nov 3, 2009)

Summary

Key Highlights

Frequently Asked Questions